Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 23

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 23
---
 We
plan to initiate quantitative research in Q2 2025 to assess the market opportunity for a potential development program for Chronic Babesiosis.
We will include a patient survey to measure self-reported prevalence of babesiosis and other relevant conditions across geographic
regions.

P&L Contract Review. We will conduct
a review of all of our supply chain and formulary contracts to determine whether it is possible to increase our margin on Arakoda without
increasing prices, or to compensate for any price adjustments which may be necessary to support repositioning efforts (see below). We
plan to introduce an 8-count bottle of ARAKODA NCD # 71475-257-02 into the supply chain in Q2.

Repositioning of Arakoda Relative to Malarone
and Generic Equivalent Atovaquone-Proguanil. A malaria demand study was conducted to assess the attractiveness and acceptability
of the Arakoda product profile and current pricing among health care providers and consumers. The product profile was well received among
both stakeholders; however, price sensitivity on out-of-pocket costs was noted among both groups. Generic atovaquone-proguanil, our primary
competitor is substantially cheaper than Arakoda for the average trip length (three weeks) and has superior formulary positioning (Tier
1 vs. Tier 3). However, generic-atovaquone proguanil does not provide the same level of confidence a traveler may experience from taking
a product with a convenient weekly dosing regimen during travel, that works everywhere in the world against all malaria species and drug-resistant
strains, and which requires only a single dose for post-exposure prophylaxis upon return from a malarious area. The value those advantages
confer needs to be communicated with key stakeholders.

Market Segment, Targeting, and Commercial Pilot.
We purchased market data to understand the malaria market landscape over the past decade and identified the current prescribers of Malarone
and the generic equivalent atovaquone-proguanil, the main generic competitor to Arakoda for malaria prophylaxis. The ARAKODA commercial
pilot program will commence on March 17, 2025, with three main objectives: 1. Increase ARAKODA awareness and communicate ARAKODA’s
value proposition. 2. Drive ARAKODA trial and usage and 3. Facilitate access and affordability. The pilot includes a three-pr